Global Epilepsy Market 2010-2014

This research has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key questions answered in this report:

• What will the market size be in 2014 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

2010-2014 Epilepsy Market

Published: February 2012
No. of Pages: 29
Price : Single User License - US$1500                  Corporate User License - US$2500



Table of Contents:
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010-2014 (US$ billion)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010